Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens
Autor(a) principal: | |
---|---|
Data de Publicação: | 1992 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Memórias do Instituto Oswaldo Cruz |
Texto Completo: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700049 |
Resumo: | Current methods for the control of the cattle tick Boophils microplus and the agent of bovine babesiosis, Babesia bovis are unsatisfactory. Effective immunological control of both parasites would have great advantages. However, naturally acquired immunity to the tick is generally unable to prevent serious production losses. A vaccine against the tick, based on a novel form of immunization, is being developed. A protective antigen has been isolated from the tick, characterized and produced as an effective, recombinant protein. A vaccine incorporating this antigen is currently undergoing field trials. In the Australian situation, improved tick control will probably increase endemic instability with respect to B. bovis. Fortunately, a trivalent, recombinant B. bovis vaccine has also been developed. This too is now undergoing pre-registration field trials. |
id |
FIOCRUZ-4_daf434a11792f6c4958c3afffd69adbc |
---|---|
oai_identifier_str |
oai:scielo:S0074-02761992000700049 |
network_acronym_str |
FIOCRUZ-4 |
network_name_str |
Memórias do Instituto Oswaldo Cruz |
spelling |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigensvaccinationBoophilus microplusBabesia bovisrecombinant antigensfield trialsCurrent methods for the control of the cattle tick Boophils microplus and the agent of bovine babesiosis, Babesia bovis are unsatisfactory. Effective immunological control of both parasites would have great advantages. However, naturally acquired immunity to the tick is generally unable to prevent serious production losses. A vaccine against the tick, based on a novel form of immunization, is being developed. A protective antigen has been isolated from the tick, characterized and produced as an effective, recombinant protein. A vaccine incorporating this antigen is currently undergoing field trials. In the Australian situation, improved tick control will probably increase endemic instability with respect to B. bovis. Fortunately, a trivalent, recombinant B. bovis vaccine has also been developed. This too is now undergoing pre-registration field trials.Instituto Oswaldo Cruz, Ministério da Saúde1992-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700049Memórias do Instituto Oswaldo Cruz v.87 suppl.3 1992reponame:Memórias do Instituto Oswaldo Cruzinstname:Fundação Oswaldo Cruzinstacron:FIOCRUZ10.1590/S0074-02761992000700049info:eu-repo/semantics/openAccessWilladsen,P.Kemp,D. H.Cobon,G. S.Wright,I. G.eng2020-04-25T17:46:58Zhttp://www.scielo.br/oai/scielo-oai.php0074-02761678-8060opendoar:null2020-04-26 02:05:10.188Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruztrue |
dc.title.none.fl_str_mv |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens |
title |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens |
spellingShingle |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens Willadsen,P. vaccination Boophilus microplus Babesia bovis recombinant antigens field trials |
title_short |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens |
title_full |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens |
title_fullStr |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens |
title_full_unstemmed |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens |
title_sort |
Successful vaccination against Boophilus microplus and Babesia bovis using recombinat antigens |
author |
Willadsen,P. |
author_facet |
Willadsen,P. Kemp,D. H. Cobon,G. S. Wright,I. G. |
author_role |
author |
author2 |
Kemp,D. H. Cobon,G. S. Wright,I. G. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Willadsen,P. Kemp,D. H. Cobon,G. S. Wright,I. G. |
dc.subject.por.fl_str_mv |
vaccination Boophilus microplus Babesia bovis recombinant antigens field trials |
topic |
vaccination Boophilus microplus Babesia bovis recombinant antigens field trials |
dc.description.none.fl_txt_mv |
Current methods for the control of the cattle tick Boophils microplus and the agent of bovine babesiosis, Babesia bovis are unsatisfactory. Effective immunological control of both parasites would have great advantages. However, naturally acquired immunity to the tick is generally unable to prevent serious production losses. A vaccine against the tick, based on a novel form of immunization, is being developed. A protective antigen has been isolated from the tick, characterized and produced as an effective, recombinant protein. A vaccine incorporating this antigen is currently undergoing field trials. In the Australian situation, improved tick control will probably increase endemic instability with respect to B. bovis. Fortunately, a trivalent, recombinant B. bovis vaccine has also been developed. This too is now undergoing pre-registration field trials. |
description |
Current methods for the control of the cattle tick Boophils microplus and the agent of bovine babesiosis, Babesia bovis are unsatisfactory. Effective immunological control of both parasites would have great advantages. However, naturally acquired immunity to the tick is generally unable to prevent serious production losses. A vaccine against the tick, based on a novel form of immunization, is being developed. A protective antigen has been isolated from the tick, characterized and produced as an effective, recombinant protein. A vaccine incorporating this antigen is currently undergoing field trials. In the Australian situation, improved tick control will probably increase endemic instability with respect to B. bovis. Fortunately, a trivalent, recombinant B. bovis vaccine has also been developed. This too is now undergoing pre-registration field trials. |
publishDate |
1992 |
dc.date.none.fl_str_mv |
1992-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700049 |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761992000700049 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0074-02761992000700049 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Instituto Oswaldo Cruz, Ministério da Saúde |
publisher.none.fl_str_mv |
Instituto Oswaldo Cruz, Ministério da Saúde |
dc.source.none.fl_str_mv |
Memórias do Instituto Oswaldo Cruz v.87 suppl.3 1992 reponame:Memórias do Instituto Oswaldo Cruz instname:Fundação Oswaldo Cruz instacron:FIOCRUZ |
reponame_str |
Memórias do Instituto Oswaldo Cruz |
collection |
Memórias do Instituto Oswaldo Cruz |
instname_str |
Fundação Oswaldo Cruz |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
repository.name.fl_str_mv |
Memórias do Instituto Oswaldo Cruz - Fundação Oswaldo Cruz |
repository.mail.fl_str_mv |
|
_version_ |
1669937660509028352 |